Oral antiviral therapy (nirmatrelvir/ritonavir or Paxlovid) is now available in Quebec for selected patients who are at high risk of progression to severe disease AND identified early (<5days) after onset of symptoms.. Beware drug-drug interactions and limited supply - our latest guidelines offer an approach for outpatient management of COVID-19 for vulnerable high-risk patients. Enjoy!
top of page
Search
Recent Posts
See AllINESSS approved the TDM of Linezolid in May 2024 It is now available in the MUHC (via HSJ labs) The ASP committee is happy to publish a...
30
The ASP chairs are happy to publish the MUHC ASP annual report 2022-2023, now available in the Resources section of the MUHC ASP website....
10
The ASP committee is happy to give you an early Christmas gift! We published the guidelines on management and treatment of Staphylococcus...
410
bottom of page
Comments